Draft Guidance on Fosinopril Sodium; Hydrochlorothiazide

This draft guidance, once finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Fosinopril Sodium; Hydrochlorothiazide

**Form/Route:** Tablets/Oral

**Recommended studies:** 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover *in-vivo*
   Strength: 20/12.5 mg
   Subjects: Normal healthy males and females, general population
   Additional Comments: Female subjects should be excluded from the studies if they are pregnant.

2. Type of study: Fed
   Design: Single-dose, two-way crossover *in-vivo*
   Strength: 20/12.5 mg
   Subjects: Normal healthy males and females, general population
   Additional comments: Female subjects should be excluded from the studies if they are pregnant.

**Analytes to measure (in appropriate biological fluid):** Metabolite fosinoprilat and hydrochlorothiazide in plasma.

**Bioequivalence based on (90% CI):** Metabolite fosinoprilat and hydrochlorothiazide

**Waiver request of in-vivo testing:** 10 mg/12.5 mg based on (i) acceptable bioequivalence studies on the 20/12.5 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

**Dissolution test method and sampling times:**

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at [http://www.fda.gov/cder/ogd/index.htm](http://www.fda.gov/cder/ogd/index.htm). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

*Recommended Aug 2005, Sept 2008*